Guanhao Biotech Co

Guanhao Biotech Co OCF Margin

The Operating Cash Flow Margin of Guanhao Biotech Co (300238.SZ) as of Nov 1, 2026 is 18.64 %. In the previous year, Operating Cash Flow Margin was 13.13 % — a change of 42.00% (higher).

OCF Margin

18.64 %

YoY

42.00%

Last updated:

Operating Cash Flow Margin of Guanhao Biotech Co is 2025 18.64 % . Operating Cash Flow Margin of Guanhao Biotech Co was 2024 13.13 % . It decreases by 42.00% higher compared to the previous year.

The Guanhao Biotech Co OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
7.04 CNY
Jan 1, 2019
21.13 CNY
Jan 1, 2020
23.76 CNY
Jan 1, 2021
25.03 CNY
Jan 1, 2022
18.81 CNY
Jan 1, 2023
13.40 CNY
Jan 1, 2024
13.13 CNY
Jan 1, 2025
18.64 CNY
The Guanhao Biotech Co OCF Margin history
YEAROCF MarginYoY
18.64 %+42.00%
13.13 %-2.01%
13.40 %-28.79%
18.81 %-24.83%
25.03 %+5.33%
23.76 %+12.44%
21.13 %+200.20%
7.04 %+68.73%
4.17 %-57.46%
9.81 %-67.31%
30.01 %-12.73%
34.38 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Guanhao Biotech Co Stock analysis

What does Guanhao Biotech Co do? Guanhao Biotech Co Ltd develops and sells regenerative medical materials and implant devices, including biological dura mater patches, chest general surgery department patching membranes (type P and type B), asepsis biological wound-surface protection membranes, type B dura matrix, and intraocular lenses. The company generates revenue through the sale of these products to healthcare providers and medical institutions. Its primary customers are hospitals and surgical departments requiring advanced regenerative solutions for wound care and ophthalmic procedures. The firm also offers related technological services as part of its product portfolio. The company focuses on regenerative medical applications, targeting segments such as neurosurgery, general surgery, and ophthalmology. Its product range addresses specific clinical needs, including dura mater repair, wound protection, and vision correction. By providing specialized medical materials, Guanhao Biotech serves healthcare facilities seeking innovative solutions for patient recovery and surgical outcomes. Guanhao Biotech's core business revolves around the production and distribution of high-value medical devices and materials. The firm's revenue streams are derived from direct sales of its regenerative medical products and associated technological services. Key segments include hospitals, surgical departments, and ophthalmic clinics that utilize its specialized membranes and lenses for patient care. Guanhao Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Guanhao Biotech Co stock

Operating Cash Flow Margin of Guanhao Biotech Co is 18.64 % in 2025.

Operating Cash Flow Margin of Guanhao Biotech Co changed from 13.13 % to 18.64 %, representing a 42.00% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Guanhao Biotech Co since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Guanhao Biotech Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Guanhao Biotech Co

All Key Metrics — Guanhao Biotech Co